GSK secured FDA approval for Hibsago (bebpirovirsen), an investigational hepatitis B therapy licensed from Ionis Pharmaceuticals, positioning the antisense oligonucleotide for a potential “functional cure” strategy. The drug targets viral genetic instructions that drive replication and viral protein production. The approval expands the competitive landscape beyond existing nucleos(t)ide analogs, which suppress but generally do not eradicate chronic infection. GSK also framed the drug as a revenue pillar tied to its broader growth plan, setting expectations for future dosing optimization and real-world uptake. For biotech and pharma teams, the read-through is twofold: regulatory pathways for RNA-targeting antivirals remain active, and payer/label dynamics will likely hinge on durability of response and standardized endpoints for functional cure claims.